Author: Tan, Emily L.C.; Ooi, Eng Eong; Lin, Chin-Yo; Tan, Hwee Cheng; Ling, Ai Ee; Lim, Bing; Stanton, Lawrence W.
Title: Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs Cord-id: kcyao9i9 Document date: 2004_4_25
ID: kcyao9i9
Snippet: Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-CoV infection. In this study, we investigated whether a panel of commercially available antiviral drugs exhibit in vitro anti–SARS-CoV activity. A drug-screening assay that scores for virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically approved compounds from several major antiviral phar
Document: Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-CoV infection. In this study, we investigated whether a panel of commercially available antiviral drugs exhibit in vitro anti–SARS-CoV activity. A drug-screening assay that scores for virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically approved compounds from several major antiviral pharmacologic classes: nucleoside analogs, interferons, protease inhibitors, reverse transcriptase inhibitors, and neuraminidase inhibitors. Complete inhibition of cytopathic effects of SARS-CoV in culture was observed for interferon subtypes, β-1b, α-n1, α-n3, and human leukocyte interferon α. These findings support clinical testing of approved interferons for the treatment of SARS.
Search related documents:
Co phrase search for related documents- acid synthesis and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
- acid synthesis and low activity: 1
- action mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- action mechanism and low activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- action mechanism view and acute respiratory syndrome: 1
- active ingredient and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- active ingredient and low activity: 1, 2
- active interferon and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
- activity difference and acute respiratory syndrome: 1, 2
- activity difference and low activity: 1, 2, 3, 4, 5
- activity vitro evidence and acute respiratory syndrome: 1, 2, 3
- acute respiratory syndrome and additional supply: 1, 2
- acute respiratory syndrome and long therapy respond: 1
- acute respiratory syndrome and low activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50
- acute respiratory syndrome and low viral challenge: 1
Co phrase search for related documents, hyperlinks ordered by date